Industry Not Sold On FDA Emerging Technology Program
Complaints Voiced About Cost And Value of Investment
Executive Summary
FDA’s calls for more generic industry participation in its Emerging Technology Program fell on deaf ears at a recent meeting, with several complaining about the costs and value of investing in new manufacturing technologies.